See the DrugPatentWatch profile for Eligard
How much does a 3‑month dose of Eligard cost?
A single 3‑month leuprolide acetate injection (Eligard) is sold in the U.S. for about $4,500–$5,000 retail, depending on the pharmacy or discount program. Generic versions, such as leuprolide acetate injections produced by other manufacturers, can be priced around $3,500–$4,000 for the same 3‑month supply.
Do insurers or Medicare cover it?
Most commercial insurance plans cover Eligard under their oncology or prostate‑cancer protocols, often with a copay or coinsurance that depends on the patient’s benefit tier. Medicare Part B typically covers the drug when it is administered by a clinician, with the patient paying the usual Part B cost‑sharing amount.
Are there cheaper alternatives or biosimilars?
Biosimilar leuprolide products such as Abarelix and Relugon have entered the market in 2024, offering prices 10–20 % lower than the brand name. In some regions, generic leuprolide acetate (e.g., Leuprolide Acetate 3 mg/1 mL) is available at a further reduced cost.
How does the price compare with other androgen‑deprivation therapies?
Compared with other hormonal agents—like Goserelin (Zoladex) and Degarelix (Firmagon)—Eligard is generally mid‑tier. Goserelin 3‑month injections average $4,000, while Degarelix 3‑month costs hover around $5,500, making Eligard a more economical option for many patients.
Can a patient qualify for a discount or assistance program?
Pfizer’s Prostate Cancer Support Program offers financial help to patients who meet income and insurance criteria. Additionally, the Patient Assistance Fund provides vouchers covering up to 90 % of the drug cost for uninsured or under‑insured patients.
What drives the price of Eligard?
Price is influenced by manufacturing costs, patent protection, and the competitive landscape. Since the original patents on leuprolide acetate expired in 2016, the market has seen several generics and biosimilars, but the brand name still commands a premium due to marketing and brand recognition.
When will the patent expire and could that change the price?
The key patents covering the formulation and administration of leuprolide acetate are set to expire in 2027, after which additional generics may enter the market. This could lower the price by 20–30 % over the next few years.
Do prices differ outside the U.S.?
In Canada, a 3‑month dose of Eligard costs about CAD 1,200–1,400, while in the U.K. the NHS supplies it at roughly £300–£400 per cycle, reflecting local pricing and procurement strategies.
Sources
1. https://drugpatentwatch.com
2. https://www.goodrx.com/eligard